Article
Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Basic & clinical pharmacology & toxicology - 1 Jun 2018
Belmonte Carmen, Ochoa Dolores, Román Manuel, Saiz-Rodríguez Miriam, Wojnicz Aneta, Gómez-Sánchez Clara Isabel, Martín-Vílchez Samuel, Abad-Santos Francisco
Abstract excerpt
The aim of this study was to investigate the effect of polymorphisms in cytochrome P450 (CYP) 2D6, CYP3A4 and CYP3A5 enzymes and in P-glycoprotein (P-gp) on the pharmacokinetics and safety of aripiprazole and, its active metabolite, dehydro-aripiprazole, in 148 healthy volunteers from six bioequivalence trials receiving a single oral dose of aripiprazole. The plasma concentrations of both analytes were measured...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
